Influenza Clinical Trials

Browse current & upcoming clinical research / studies on Influenza. There are a total of 689 clinical trials for Influenza in 47 countries with 37 trials currently in the United States. 59 are either active and/or recruiting patients or have not yet been completed. Click the title of each study to get the complete details on eligibility, location & other facts about the study.

Other clinical trials

Interventional trials
Determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments.
Observational trials
Address health issues in large groups of people or populations in natural settings.
Participants are currently being recruited and enrolled.
Active, not recruiting
Study is ongoing (i.e., patients are being treated or examined), but enrollment has completed.
Not yet recruiting
Participants are not yet being recruited or enrolled.
Enrolling by invitation
Participants are being (or will be) selected from a predetermined population.
The study has concluded normally; participants are no longer being examined or treated (i.e., last patient's last visit has occurred).
Study halted prematurely, prior to enrollment of first participant.
Recruiting or enrolling participants has halted prematurely but potentially will resume.
Recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated.
September 2014 - October 2016
Apomivir® is extracted from a proprietary spirulina strain, FEM-101, a kind of blue cyanobacterium with patented freeze-thaw lysis and extraction method. According to the preclinical studies, Apomivir® have been proven to have excellent broad-spectrum anti-viral ability, especially for seasonal influenza viruses (Influenza virus A and B) that may cause illness, paralysis and even death, especially in children and elderly people. This phase II study is designed to evaluate the efficacy and safety of Apomivir® (120 mg b.i.d.) in subjects with seasonal influenza.
Sponsor: Far East Bio-Tec Co., Ltd
Study type: Interventional
March 2014 - December 2015
One dose of escalating strengths of an investigational influenza vaccine VAX2012Q (Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine) will be evaluated for tolerability and immunogenicity in healthy adults 18-40 years of age.
Sponsor: VaxInnate Corporation
Study type: Interventional
March 2014 - April 2014
This clinical trial is a phase 1/2 study of a single intramuscular injection of TAK-850 in healthy Japanese adult participants
Sponsor: Takeda
Study type: Interventional
March 2014 -
To evaluate the safety, tolerability and pharmacokinetics (PK) of single,and repeat escalating doses of FF-3 dry powder administered via inhalation in healthy adult subjects
Sponsor: Autoimmune Technologies, LLC
Study type: Interventional
March 2014 - December 2014
Prospective, open-labelled study which will enrol 360 participants in four groups of 80 participants including: HIV-uninfected adults without evidence of TB; HIV-infected adults without any evidence of TB; HIV-uninfected adults with concurrent microbiologic confirmed TB, HIV-infected adults with concurrent microbiologic confirmed TB. Participants will receive the recommended seasonal 2013 un-adjuvanted Trivalent Influenza Vaccine (TIV). At 3 visits, blood will be collected for determination of immune responses. Objective: • To determine the effect of HIV-infection, tuberculosis (TB) and HIV-TB co-infection on immune responses
Sponsor: University of Witwatersrand, South Africa
Study type: Interventional
February 2014 - August 2014
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacokinetics of single escalating doses of VIS410 in healthy volunteers.
Sponsor: Visterra, Inc.
Study type: Interventional
February 2014 - July 2014
This study is to evaluate the efficacy of CT-P27 measured by quantitative PCR viral load from nasopharyngeal mucosa, compared to placebo.
Sponsor: Celltrion
Study type: Interventional
January 2014 - June 2014
Despite currently available antivirals, influenza causes significant morbidity and mortality, with 226,000 excess hospitalizations and 30,000-50,000 deaths each year in the United States alone, and more therapies are needed in the armamentarium of anti-influenza medications including humoral immunity-based agents. This study will evaluate the pharmacokinetics of an anti-influenza hyperimmune intravenous immunoglobulin. Beginning with a low dose, subjects will receive anti-influenza intravenous immunoglobulin (FLU-IVIG) and evaluated on Study Days 0, 3, 7, 14, and 28. The safety and tolerability is evaluated using symptoms, clinical laboratory tests, and pharmacokinetics. Utilizing serum antibody responses as determined by hemagglutination inhibition (HAI) assays, the dose will be escalated as immunogenicity is established.
Sponsor: National Institutes of Health Clinical Center (CC)
Study type: Interventional
January 2014 -
This is a single blinded placebo controlled phase I study, to assess the safety and immunogenicity of co-administration of the candidate influenza vaccine MVA-NP+M1 with the Viroflu® seasonal influenza vaccine. All volunteers recruited will be healthy adults aged 18 and over.
Sponsor: University of Oxford
Study type: Interventional
January 2014 - December 2014
The purpose of this study is to determine if favipiravir is effective in reducing the time to resolution of influenza symptoms.
Sponsor: MDVI, LLC
Study type: Interventional
Home  •  Browse by Condition  •  Search Clinical Trials
The information found on this site has been provided by in accordance with their terms & conditions. Neither we (, the United States Government, U.S. Department of Health and Human Services, National Institutes of Health, National Library of Medicine, nor any of its agencies, contractors, subcontractors or employees of the United States Government make any warranties, expressed or implied, with respect to data found on this site, and, furthermore, assume no liability, or the results of such use, of any part of the data.